Physician profile
Mark Mcbride
NPI 1659381077
$2,584,921.82
in general payments reported to CMS, 2019-2025
13 companies · $619K in 2025
The $619K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301K · 2020: $266K · 2021: $376K · 2022: $459K · 2023: $563K · 2024: $600 · 2025: $619K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.2M · Consulting Fee: $26K · Food and Beverage: $1,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,154,880.11 |
| Consulting Fee | $26,200.00 |
| Food and Beverage | $1,660.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Encore Medical, Lp | $2,582,400.89 | 2019-2025 | Djo Surgical |
| Linvatec Corporation | $1,198.96 | 2019-2023 | Biobrace 23mm |
| Medtronic, INC. | $700.00 | 2023 | |
| Zimmer Biomet Holdings, INC. | $144.29 | 2022-2024 | Avenir |
| Davol INC. | $116.20 | 2022 | |
| Lima USA, INC. | $100.31 | 2021 | |
| Stryker Corporation | $97.91 | 2022-2023 | Mako |
| Acumed LLC | $68.55 | 2022 | |
| Illuminoss Medical, INC. | $34.58 | 2021 | |
| Convatec INC. | $20.63 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $18.48 | 2025 | Exparel |
| Heron Therapeutics, INC. | $16.05 | 2021 | |
| Biocomposites INC | $4.97 | 2025 | Stimulan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.